Claims
- 1. A pharmaceutically acceptable composition comprising more than 0.2 mg/mL Tissue Factor Pathway Inhibitor (TFPI) and a solubilizing agent, said solubilizing agent selected from the group consisting of:
- (a) greater than 150 mM sodium chloride;
- (b) isocitrate ion;
- (c) glutamate;
- (d) succinate ion;
- (e) imidazole; and
- (f) SDS, wherein the composition is hypertonic.
- 2. The composition of claim 1 wherein TFPI is present at a concentration of at least 1 mg/mL.
- 3. The composition of claim 1 wherein TFPI is present at a concentration of at least 10 mg/mL.
- 4. The composition of claim 1 further comprising a secondary solubilizer, said secondary solubilizer selected from the group consisting of
- mannitol and
- sorbitol.
- 5. The composition of claim 1 further comprising sodium phosphate at a concentration greater than 20 mM.
- 6. The composition of claim 1 wherein the composition comprises 0.5M Na.sub.3 PO.sub.4.
- 7. The composition of claim 1 wherein the pH of the composition is below pH 7.0.
- 8. The composition of claim 7 wherein the pH of the composition is pH 4.5 or below.
- 9. The composition of claim 1 wherein the solubilizer is acetate ion and the acetate ion is present in the composition as sodium acetate or potassium acetate at a concentration from 5 mM to 20 mM.
- 10. A pharmaceutically acceptable composition wherein the composition is hypertonic and comprises more than 0.2 mg/ml TFPI and 0.5M NaCl.
- 11. A pharmaceutically acceptable composition wherein the composition is hypertonic and comprises 0.5M sodium citrate and more than 0.2 mg/ml TFPI.
- 12. A pharmaceutically acceptable composition comprising more than 0.2 mg/ml TFPI and at least 0.5M sodium chloride.
- 13. A pharmaceutically acceptable composition comprising more than 0.2 mg/ml TFPI and citrate ion wherein the citrate ion is present in the composition as sodium citrate or potassium citrate at a concentration of from 100 mM to 500 mM.
- 14. A pharmaceutically acceptable composition comprising more than 0.2 mg/ml TFPI and sodium dodecylsulfate wherein the sodium dodecyl sulfate is present in the composition at a concentration of 0.001% to 0.1% (weight/volume).
Parent Case Info
This applications is a continuation of application Ser. No. 08/477,677, filed Jun. 7,1995, now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5276015 |
Khouri et al. |
Jan 1994 |
|
5358708 |
Patel et al. |
Oct 1994 |
|
5503827 |
Woog et al. |
Apr 1996 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
9325230 |
Dec 1993 |
WOX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
477677 |
Jun 1995 |
|